Navigation Links
New Gel Treats Precancerous Skin Condition in Days: Study
Date:3/14/2012

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, March 14 (HealthDay News) -- A newly approved gel appears effective in treating a condition called actinic keratosis, which is a common precursor to squamous cell skin cancer, a new study finds.

Earlier topical treatments took weeks or even months to treat the condition, but the new product -- Picato (ingenol mebutate) gel -- can work in a matter of days, according to the report in the March 15 issue of the New England Journal of Medicine.

"There are a number of agents available to treat precancerous skin lesions," said study author Dr. Mark Lebwohl, a professor and chairman of dermatology at Mount Sinai School of Medicine in New York City.

"Most of the other ones are applied over a period of weeks to months and have a reaction that lasts for a long time, so it interferes with your life for a good period of time. This one is unique in that it is applied for only one to three days," he said.

The U.S. Food and Drug Administration approved Picato for use on actinic keratoses in January. The new study was funded by LEO Pharma, the maker of Ingenol.

For the study, more than 900 people with actinic keratoses on their face or scalp, or elsewhere on their body (trunk, arms or legs) were randomly assigned to treatment with either Picato or an inactive placebo.

The researchers found that when used on the face or scalp, the gel cleared the condition nearly 43 percent of the time, compared with nearly 4 percent for the placebo.

When used on the trunk or extremities, the gel was again more effective than placebo -- about 34 percent for the gel versus nearly 5 percent for the placebo, the study authors noted.

Local skin reactions such as redness and crustiness developed within several days, but were gone quickly, and side effects were mild to moderate and went away without any problem, according to the report.

And because treatment takes less time, patients are more likely to adhere to their treatment, said study co-author Dr. Neil Swanson, director of dermatologic surgery at Oregon Health and Science University in Portland.

"It is an option to treat these lesions, a good percentage of which will go on to evolve to skin cancer," Swanson said.

In addition to skin gels, doctors treat actinic keratosis in other ways that include burning or scraping with an electric or laser device, cutting the tumor out, or freezing the tumor in a procedure called cryotherapy.

Commenting on the study treatment, Dr. Doris Day, a dermatologist at Lenox Hill Hospital in New York City, said that "it is efficacious and it's good for patients who can't tolerate other treatment."

However, Day said she would most likely use this gel in combination with other methods to treat the condition.

"I don't think I would use it as monotherapy," she said. "I don't think it penetrates deeply into the skin. So I would mix this with my other treatments such as laser and cryotherapy."

Day stressed that it is important to treat actinic keratosis before it becomes skin cancer.

More information

To learn about actinic keratosis, visit the U.S. National Library of Medicine.

SOURCES: Mark Lebwohl, M.D., professor and chairman of dermatology, Mount Sinai School of Medicine, New York City; Neil Swanson, M.D., director, dermatologic surgery, Oregon Health and Science University, Portland; Doris Day, M.D., dermatologist, Lenox Hill Hospital, New York City; March 15, 2012, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Aderans Research Treats One-Hundredth Subject in Clinical Study
2. High-fat ketogenic diet effectively treats persistent childhood seizures
3. Ayurvedic Cooking, Massages and Yoga -- Relaxing for Children Charity -- Retreats at an Ashram in India
4. Combining radiation therapy, chemotherapy safely treats head and neck cancer patients
5. Those Sweet Pet Treats May Foster Fatness
6. In U.S., Salmonella Is on the Rise While E. Coli Retreats
7. New Drug Effectively Treats Hepatitis C
8. New procedure treats atrial fibrillation
9. Radiofrequency ablation safely and effectively treats Barretts esophagus
10. Paired drugs kill precancerous colon polyps, spare normal tissue
11. New form of endoscopic scanning improves detection of precancerous condition
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Gel Treats Precancerous Skin Condition in Days: Study
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: